May 08, 2018
Valeant Will Become Bausch Health Companies Inc.
Apr 12, 2018
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
Mar 08, 2018
Valeant To Participate At The 2018 Barclays Global Healthcare Conference
Feb 27, 2018
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
Jan 25, 2018
Valeant Will Reduce Debt By An Additional $200 Million
Jan 12, 2018
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
Jan 09, 2018
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference
Jan 03, 2018
Valeant Pays Down $300 Million Of Senior Secured Term Loans
Jan 03, 2018
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference
Dec 29, 2017
Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation
Dec 18, 2017
Bausch + Lomb Begins Distribution Of VYZULTA(TM) (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers
Nov 14, 2017
Ortho Dermatologics Announces Aspire Higher Scholarship Honorees
Nov 10, 2017
Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.
Nov 06, 2017
Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
Oct 31, 2017
Valeant Will Reduce Debt By Additional $125 Million
Sep 15, 2017
Valeant Commits $200,000 to Support Hurricane Relief Efforts
Sep 06, 2017
Valeant To Participate At The Morgan Stanley Global Healthcare Conference
Aug 16, 2017
Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility
Jul 27, 2017
Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Jun 19, 2017
John Paulson Joins Valeant Board Of Directors